Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two treatment strategies with ribavirin for chronic and severe acute hepatitis E
2015-000699-91Phase 3Completed
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jul 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ribavirin in chronic hepatitis E and hepatitis E (HEV) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Sustained virological response. Started Jul 2015; status: completed.
02
Drugs
ribavirin
03
Conditions
chronic hepatitis Ehepatitis E (HEV)
Beyond the preview
Go deeper on 2015-000699-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000699-91.